The Latest Cardiac and Vascular News
The RESTORE trial will test the safety and efficacy of the HARPOON™ Beating Heart Mitral Valve Repair System. New minimally invasive device could reduce pain, complications and recovery time for mitral valve repair surgery. Hoag is one of only 40 sites in the world selected for this trial. NEWPORT BEACH, […]
George Medicines initiates two Phase III trials of triple combination candidate to treat hypertension Novel proprietary triple low-dose combination pill has been shown to outperform traditional blood pressure treatments without additional side effects in earlier clinical research Lead candidate in Company’s pipeline of proprietary fixed-dose combination therapies targeting high unmet need in large patient populations suffering from non-communicable diseases such as CVD and Diabetes London, UK, 1 July 2021 – George Medicines, a late-stage drug development company focused […]
REGULATED INFORMATION – INSIDE INFORMATION 1 July 2021, 07:00 am CEST Interim data from 26 patients in the Roll-In Cohort reconfirm positive outcomes against all primary endpointsi Over 90% reduction in mean frequency of therapeutic paracentesis versus baseline All patients experienced at least 50% reduction in mean frequency of therapeutic paracentesis per month versus baseline Clinically important improvement in quality of life maintained even up to 12 months post-implantation Safety profile remains in line […]
Merck and NGM will continue their research, discovery and development collaboration with a narrower scope, focused primarily on retinal and cardiovascular and metabolic (CVM) targets of interest to Merck Merck will continue to advance MK-3655, an FGFR1c/KLB agonistic antibody, currently in an ongoing global Phase 2b clinical trial in patients […]
HANOVER, Germany–(BUSINESS WIRE)–Cardior Pharmaceuticals GmbH, a clinical-stage biotech company focused on the development of non-coding RNA (ncRNA) based therapeutics for patients with cardiac diseases, today announced the appointment of Rahul Agrawal, MD, as Chief Medical Officer. Dr. Agrawal brings more than 20 years of industry experience from global and senior medical […]
Gene therapy industry veteran Leone Patterson joins Tenaya as Chief Financial and Business Officer Cardiologist Matthew Pollman appointed as Senior Vice President, Clinical Development SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Tenaya Therapeutics, a biotechnology company with a mission to discover, develop and deliver curative therapies that address the underlying causes of heart […]
Atlas, Carta’s AI-assisted data abstraction software, seamlessly automates submission to the ACC’s CathPCI clinical data registry, allowing healthcare organizations to maximize the benefits of registry contributions SAN FRANCISCO–(BUSINESS WIRE)–Carta Healthcare, a provider of artificial intelligence (AI)-powered clinical data abstraction technology and services, today announced that it is now a certified […]
American Heart Association consortium advances development of evidence-based health tech solutions PORTLAND, Maine–(BUSINESS WIRE)–Ginkgo Heart, LLC, has joined the American Heart Association Center for Health Technology & Innovation’s (the Center) Innovators’ Network. The Center is focused on building and fostering health technology relationships to develop innovative and scalable solutions. The […]
STOCKHOLM, June 30, 2021 /PRNewswire/ — Mentice AB (publ) a leading supplier of high-technology solutions for simulation in the medical sector with focus on interventional procedures, has entered into an agreement with Baylis Medical Company (“Baylis”) to provide simulation solutions. Based on this order, Mentice will support Baylis’ product portfolio for transseptal puncture procedures with Mentice […]
MINNEAPOLIS, June 29, 2021 (GLOBE NEWSWIRE) — CVRx, Inc. (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative and minimally invasive neuromodulation solutions for patients with cardiovascular diseases, announced today the upsize and pricing of its initial public offering of 7,000,000 shares of its common stock […]
